Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: Two case reports

Journal of the American Academy of Dermatology

Volumn 47, Issue 4, 2002, Pages S229-S235

  Zampogna, Jennifer C ^a   Flowers, Franklin P ^a   Roth, William I ^a   Hassenein, Ashraf M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; GENITAL SYSTEM DISEASE; HISTOPATHOLOGY; HUMAN; MALE; MINIMALLY INVASIVE SURGERY; MORBIDITY; PAGET SKIN DISEASE; PERINEUM; PRIORITY JOURNAL; SKIN DISEASE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTERFERON INDUCERS; MALE; MIDDLE AGED; PAGET'S DISEASE, EXTRAMAMMARY; PERINEUM; SCROTUM; SKIN NEOPLASMS;

EID: 0036786777     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.126584     Document Type: Article

References (25)

1. Balducci L, Crawford D, Smith G, Lambuth B, McGehee R, Hardy C. Extramammary Paget's disease: an annotated review. Cancer Invest 1988;6:293-303.
2. Wick M, Swanson P, Barnhill R. Sweat gland tumors. In: Barnhill RL, editor. Textbook of dermatopathology. New York: McGraw-Hill; 1998. p. 646-7, 652.
3. Helm KF, Goellner JR, Peters MS. Immunohistochemical stains in extramammary Paget's disease. Am J Dermatopathol 1992;14:402-7.
4. Coldiron BM, Goldsmith BA, Robinson JK. Surgical treatment of extramammary Paget's disease: a report of six cases and a reexamination of Mohs micrographic surgery compared with conventional surgical excision. Cancer 1991;67:933-8.
5. Kageyama N, Izumi AK. Bilateral scrotal extramammary Paget's disease in a Chinese man. Int J Dermatol 1997;36:695-7.
6. Zollo JD, Zeitouni NC. The Roswell Park Cancer Institute experience with extramammary Paget's disease. Br J Dermatol 2000;142:59-65.
7. Chen YH, Wong TW, Lee JY. Depigmented genital extramammary Paget's disease: a possible histogenetic link to Toker's clear cells and clear cell papulosis. J Cutan Pathol 2001;28:105-8.
8. Koh KBH, Nazarina AR. Paget's disease of the scrotum: report of a case with underlying carcinoma of the prostate. Br J Dermatol 1995;133:306-7.
9. Chaudhuri SR, Smoller BR. Extramammary Paget's disease: diagnosis and disease pattern. Cutis 1992;50:195-6.
10. Burrows NP, Jones DH, Hudson PM, Pye RJ. Treatment of extramammary Paget's disease by radiotherapy. Br J Dermatol 1995;132:970-2.
11. Allan SJR, McLaren K, Aldridge RD. Paget's disease of the scrotum: a case exhibiting positive prostate-specific antigen staining and associated prostatic adenocarcinoma. Br J Dermatol 1998;138:689-91.
12. Becker-Wegerich PM, Fritsch C, Schulte KW, Megahed M, Neuse W, Goerz G, et al. Carbon dioxide laser treatment of extramammary Paget's disease guided by photodynamic diagnosis. Br J Dermatol 1998;138:169-72.
13. Henta T, Itoh Y, Kobayashi M, Ninomiya Y, Ishibashi A. Photodynamictherapy for inoperable vulval Paget's disease using deltaaminolevulinic acid: successful management of a large skin lesion. Br J Dermatol 1999;141:347-9.
14. Bewley AP, Bracka A, Staughton RCD, Bunker CB. Extramammary Paget's disease of the scrotum: treatment with topical 5-fluorouracil and plastic surgery. Br J Dermatol 1994;131:445-6.
15. Perez MA, LaRossa DD, Tomaszewski JE. Paget's disease primarily involving the scrotum. Cancer 1989;63:970-5.
16. Dahl MV. Imiquimod: an immune response modifier. J Am Acad Dermatol 2000;43:S1-S5.
17. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waidschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000;203:55-65.
18. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 1996;74:1482-6.
19. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinoline amine. Cancer Res 1992;52:3528-33.
20. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-S11.
21. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000;26:577-9.
22. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
23. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol 2001;137:14-6.
24. Still JM, editor. Immune response modifier therapy: treatment of warts, basal cell carcinoma, and actinic keratosis. In: Skin and allergy news (proceedings of a clinical roundtable). Rockville (MD): International Medical News Group; 2001. p. 1-16.
25. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6.